Inflammatory Markers are Quickly Improved by Tocilizumab in Early Polymyalgia Rheumatica and Might Predict Early Response to Interleukin-6 Blockade
| Autor: | Valérie Devauchelle-Pensec, Divi Cornec, Alain Saraux, Yves Renaudineau, Guillermo Carvajal Alegria |
|---|---|
| Přispěvatelé: | Michel, Geneviève, CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Lymphocytes B, Autoimmunité et Immunothérapies (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-LabEX IGO Immunothérapie Grand Ouest, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Laboratoire d'Immunologie et Immunothérapie [Brest], Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty [SDV.IMM] Life Sciences [q-bio]/Immunology education Inflammation Gastroenterology Polymyalgia rheumatica 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Tocilizumab Rheumatology immune system diseases Internal medicine medicine Immunology and Allergy 10. No inequality Interleukin 6 skin and connective tissue diseases health care economics and organizations Original Research 030304 developmental biology Γ-globulins 030203 arthritis & rheumatology Autoimmune disease 0303 health sciences biology business.industry Interleukin-6 Autoantibody Acute-phase protein medicine.disease Acute phase reactants 3. Good health chemistry biology.protein [SDV.IMM]Life Sciences [q-bio]/Immunology medicine.symptom business |
| Zdroj: | Rheumatology and Therapy Rheumatology and Therapy, 2021, ⟨10.1007/s40744-021-00299-8⟩ Rheumatology and Therapy, Springer, 2021, ⟨10.1007/s40744-021-00299-8⟩ |
| ISSN: | 2198-6576 2198-6584 |
| DOI: | 10.1007/s40744-021-00299-8⟩ |
| Popis: | Introduction It is unclear whether polymyalgia rheumatica (PMR) should be considered an inflammatory disease or an autoimmune disease. Methods Eighteen untreated early PMR patients and 18 sex- and age-matched healthy controls (HCs) were included. PMR patients received tocilizumab from week 0 to week 12 and glucocorticoids from week 12 to week 24. Leukocytes, neutrophils, platelets, hemoglobin, γ-globulins, IgG, IgA, and IgM were compared between the PMR patients and HCs and before and after tocilizumab treatment in the PMR group. Results The mean age was 68 ± 7 and 66 ± 11 years, and the mean serum C-reactive protein level was 82 ± 16 and 5 ± 2 mg/l for PMR patients and HCs, respectively. At inclusion, leukocytes (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink